Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.95 |
| ▸ | MAOA | P21397 | 3/20 | 0.77 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164263 | 1.00 | MAOB (0.95) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL10678830 | 1.00 | MAOB (0.95) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL3767602 | 0.98 | MAOB (1.00) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL9798973 | 0.93 | MAOB (0.91) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL4022346 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL4020067 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL4021564 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL20251158 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL4016462 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER | |
| SCHEMBL4016540 | 0.90 | MAOB (0.76) | MAOBMAOAHTR2ASIGMAR1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908849-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA | 2017-06-15 | — | — | US | disclosed |
| US-9421177-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011020116-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | MAOB 3458/4885MAOA 3771/4885HTR2A 2102/4885 |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | MAOB 3458/4885MAOA 3771/4885HTR2A 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.